Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD

Fig. 3

Evolution of TRPC1 and TRPC3 mRNA and protein expression levels in EDL muscles from WT and DMDmdx rats during post-natal development. A and B Relative levels of TRPC1 and TRPC3 mRNAs expression in EDL muscle extracts from WT and DMDmdx rats of 1.5 to 7 months of age. Results were normalized to HPRT1 mRNA expression. C and D Relative levels of protein expression of TRPC1 and TRPC3 in EDL muscle homogenates from WT and DMDmdx rats of 1.5–7 months of age. Representative films exposed to immunoblots are reported below histograms (obtained for muscle extracts from 6 WT and 6 DMDmdx rats of 1.5 months of age). A–D Each bar represents mean value ± SEM calculated for N animals (N indicated at the bottom of the corresponding bar). For each age and genotype, immunoblots were realized in a minimum of 3 replicates. *: significantly different from mean value measured in age-matched WT animals. $: significantly different from mean value measured in animals from the same genotype of 1.5 months of age. P < 0.05, Kruskal–Wallis and bilateral Conover-Iman post-hoc test

Back to article page